Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.29B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.08M
Average 3.00M
Returns on capital
Ocular Therapeutix, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-40.6%
avg 113.0%
ROIC
-35.5%
avg -63.2%
ROA
-32.9%
avg -56.0%
Analysis
ROA is currently the strongest return metric at -32.9% versus its period average of -56.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Pravin U. Dugel | Executive Chairman, President & Chief Executive Officer | USD 1.77M | 62 | — | — |
Donald Notman Jr. | Chief Operating Officer (Leave of Absence) | USD 969.18K | — | — | — |
Nadia K. Waheed | Chief Medical Officer | USD 935.8K | 49 | — | — |
Sanjay Nayak MBBS | Chief Strategy Officer | USD 845.65K | 56 | — | — |
Steve Meyers | Chief Commercial Officer | USD 808.68K | — | — | — |
Jeffrey S. Heier | Chief Scientific Officer | USD 676.55K | 65 | 307.46K | 0.14% |
Jason Robins | CFO & Principal Accounting Officer | — | 49 | — | — |
William H. Ransone | Vice President of Global Sales & Marketing | — | — | — | — |
William S. Slattery Jr. | Vice President of Investor Relations | — | — | — | — |
Peter K. Jarrett | Chief Technical Officer | — | 69 | — | — |
Todd Anderman | Chief Legal Officer & Corporate Secretary | — | 44 | 140.48K | 0.06% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 8, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$461,354.14
Sells
29
$3.25M
Net Transaction Value
−$2.79M
Net selling
Most Active
Kaiser Peter
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 5, 26Nov 5, 2026 | Saroj Namrata Direct | Sell | $231.7K$231,673.50 |
| Oct 8, 26Oct 8, 2026 | Anderman Todd Direct | Sell | $87.4K$87,363.36 |
| Oct 2, 26Oct 2, 2026 | Kaiser Peter Direct | Sell | $70.4K$70,429.50 |
| Oct 2, 26Oct 2, 2026 | Heier Jeffrey S. Direct | Sell | $76.6K$76,626.45 |
| Aug 31, 26Aug 31, 2026 | Notman Donald Direct | Sell | $11.3K$11,253.76 |
| Aug 24, 26Aug 24, 2026 | Kaiser Peter Direct | Sell | $32.7K$32,686.95 |
| Aug 24, 26Aug 24, 2026 | Nayak Sanjay Direct | Sell | $20.4K$20,449.66 |
| Aug 24, 26Aug 24, 2026 | Heier Jeffrey S. Direct | Sell | $35.5K$35,530.88 |
| Aug 24, 26Aug 24, 2026 | Dugel Pravin Direct | Sell | $233.2K$233,159.73 |
| Jun 3, 26Jun 3, 2026 | Waheed Nadia Direct | Sell | $122.6K$122,627.56 |
1–10 of 30
Summary
Insiders reported 1 buys worth $461,354.14 and 29 sells worth $3.25M over the last 12 months. That adds up to net selling of $2.79M. Kaiser Peter was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +0.2% | +80.5% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +0.2% over three years. Forward estimates point to Revenue at +80.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Ocular Therapeutix, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about OCUL's management, answered from reported figures.
Who manages OCUL?
Ocular Therapeutix, Inc. (OCUL) lists 11 active executives. The top listed executive is Jason Robins, CFO & Principal Accounting Officer.
Are OCUL insiders buying or selling?
Recent insider activity shows net buying of $88.59M.
Continue the stock analysis
Jump to another research area for this company.